279 related articles for article (PubMed ID: 18086153)
1. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study.
Salam NK; Huang TH; Kota BP; Kim MS; Li Y; Hibbs DE
Chem Biol Drug Des; 2008 Jan; 71(1):57-70. PubMed ID: 18086153
[TBL] [Abstract][Full Text] [Related]
2. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells.
Bernardo A; Bianchi D; Magnaghi V; Minghetti L
J Neuropathol Exp Neurol; 2009 Jul; 68(7):797-808. PubMed ID: 19535992
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma in malignant diseases.
Wang T; Xu J; Yu X; Yang R; Han ZC
Crit Rev Oncol Hematol; 2006 Apr; 58(1):1-14. PubMed ID: 16388966
[TBL] [Abstract][Full Text] [Related]
6. Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists.
Tanrikulu Y; Rau O; Schwarz O; Proschak E; Siems K; Müller-Kuhrt L; Schubert-Zsilavecz M; Schneider G
Chembiochem; 2009 Jan; 10(1):75-8. PubMed ID: 19067454
[No Abstract] [Full Text] [Related]
7. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
8. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
Ahn JH; Shin MS; Jung SH; Kang SK; Kim KR; Rhee SD; Jung WH; Yang SD; Kim SJ; Woo JR; Lee JH; Cheon HG; Kim SS
J Med Chem; 2006 Jul; 49(15):4781-4. PubMed ID: 16854085
[TBL] [Abstract][Full Text] [Related]
9. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
Zieleniak A; Wójcik M; Woźniak LA
Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
[TBL] [Abstract][Full Text] [Related]
11. Protein polarization is critical to stabilizing AF-2 and helix-2' domains in ligand binding to PPAR-gamma.
Ji CG; Zhang JZ
J Am Chem Soc; 2008 Dec; 130(50):17129-33. PubMed ID: 19007119
[TBL] [Abstract][Full Text] [Related]
12. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087
[TBL] [Abstract][Full Text] [Related]
13. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
15. Quantitative structure-activity relationships for PPAR-gamma binding and gene transactivation of tyrosine-based agonists using multivariate statistics.
Giaginis C; Theocharis S; Tsantili-Kakoulidou A
Chem Biol Drug Des; 2008 Oct; 72(4):257-64. PubMed ID: 18793305
[TBL] [Abstract][Full Text] [Related]
16. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
Gani OA; Sylte I
Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
[TBL] [Abstract][Full Text] [Related]
17. Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity.
Choi J; Ko Y; Lee HS; Park YS; Yang Y; Yoon S
Eur J Med Chem; 2010 Jan; 45(1):193-202. PubMed ID: 19879669
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears.
Mao Z; Ong AC
Nephron Clin Pract; 2009; 112(4):c230-41. PubMed ID: 19546582
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.
Xiao J; Leung JC; Chan LY; Guo H; Lai KN
Nephrol Dial Transplant; 2009 Jul; 24(7):2067-77. PubMed ID: 19155534
[TBL] [Abstract][Full Text] [Related]
20. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
